Table 2.
Nanoparticles evaluated in clinical trials.
| Nanoparticles | Payloads | Clinical Stages | Indications | Ref |
|---|---|---|---|---|
| Liposome (L-BLP25) | MUC-1, tecemotide monophosphoryl lipid A | Terminated after phase III | NSCLC | [87,88,89] |
| Liposome (AS15) | MAGE-A3, CpG 7909 monophosphoryl lipid A | Terminated after phase III | Melanoma, NSCLC | [90,91,92] |
| Liposome (ISCOMATRIX) | NY-ESO-1 | Terminated after Phase II | Melanoma | [96] |
| Liposome (DPX) | HLA-A2, Survivin polynucleotide | Phase I/II | Ovarian cancer | [93,94,95] |
| Cholesteryl pullulan (CHP) | HER-2 protein | Phase I/II | Esophageal cancer | [97] |
| Virus-like particles (VLPs) | Melan-A/MART-1, CpG | Phase I/II | Melanoma | [98,99] |